Published: June 4, 2025Category: Lung Cancer Research Introduction to Neoadjuvant Nivolumab Plus Chemotherapy in CheckMate 816 The CheckMate 816 trial offers new findings on treating resectable lung cancer with neoadjuvant nivolumab plus chemotherapy. For example, it was presented at ASCO 2025 and published in the New England Journal of Medicine. Therefore, this study shows how … Continue reading Neoadjuvant Nivolumab Plus Chemotherapy in Lung Cancer: CheckMate 816 Update at ASCO 2025